dc.contributor
Institut Català de la Salut
dc.contributor
[Martín-Saladich Q, Hammawa K] Grup de Recerca d’Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat de Teràpia de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Radiodiagnòstic, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Bellaterra, Spain. Department of Information and Communication Technologies, Pompeu Fabra University, Barcelona, Spain. [Pareto D] Secció de Neuroradiologia, Servei de Radiodiagnòstic, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Institut Diagnòstic per la Imatge (IDI), Barcelona, Spain. Grup de Recerca de Neuroradiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Simó R, Ciudin A] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBER-DEM), Instituto de Salud Carlos III, Madrid, Spain. [Aparicio C, de la Calle Vargas E, Aguadé-Bruix S] Grup de Recerca d’Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat de Teràpia de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Radiodiagnòstic, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Bellaterra, Spain. [Giralt M, Ramirez-Serra C] Grup de Recerca de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Bellaterra, Spain. [Herance JR] Grup de Recerca d’Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat de Teràpia de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Radiodiagnòstic, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanotecnología (CIBER-BBN), Instituto de Salud Carlos III, Madrid, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Martín-Saladich, Queralt
dc.contributor.author
Hammawa, Khadija
dc.contributor.author
de la Calle Vargas, Elena
dc.contributor.author
Aguade Bruix, Santiago
dc.contributor.author
Pareto, Deborah
dc.contributor.author
Simó Canonge, Rafael
dc.contributor.author
Ciudin Mihai, Andreea
dc.contributor.author
Aparicio Gómez, Carolina
dc.contributor.author
Giralt Arnaiz, Marina
dc.contributor.author
Ramírez Serra, Clara
dc.contributor.author
Herance, Jose Raul
dc.date.accessioned
2025-10-01T01:33:39Z
dc.date.available
2025-10-01T01:33:39Z
dc.date.issued
2025-08-07T08:19:50Z
dc.date.issued
2025-08-07T08:19:50Z
dc.identifier
Martín-Saladich Q, Pareto D, Simó R, Ciudin A, Aparicio C, Hammawa K, et al. Brain [18F]FDG uptake patterns in type 2 diabetes: new phenotypes relating to biomarkers of cognitive impairment. Brain Commun. 2025 Jun;7(3):fcaf213.
dc.identifier
http://hdl.handle.net/11351/13504
dc.identifier
10.1093/braincomms/fcaf213
dc.identifier
001507804800001
dc.identifier.uri
http://hdl.handle.net/11351/13504
dc.description.abstract
Brain function; Cognitive impairment; Insulin resistance
dc.description.abstract
Funció cerebral; Deteriorament cognitiu; Resistència a la insulina
dc.description.abstract
Función cerebral; Deterioro cognitivo; Resistencia a la insulina
dc.description.abstract
Previous studies in patients without Type 2 diabetes suggest that brain hypo- and hypermetabolic regions may indicate risk for cognitive disorders. We aimed to study these brain glucose uptake patterns in Type 2 diabetes to assess cognitive disorder risk and improve personalized management. Six hyper- and three hypometabolic regions were obtained through statistical parametric mapping, with cerebellar vermis and right superior temporal gyrus being the most relevant areas, respectively. Such allowed identification of two phenotypes via k-means clustering: brain hypometabolic dominant (bU[−]) and hypermetabolic dominant (bU[+]). bU[−] displayed elevated markers of both Type 2 diabetes and cognitive disorders, specifically of secreted frizzled-related protein 1, a protein related to different neuronal pathologies. A classifier was developed (area under the curve = 0.84, true positive rate = 0.81 and true negative rate = 0.78) using a combination of biochemical features. Type 2 diabetes patients exhibit hypo- and hypermetabolic brain regions that phenotype into bU[−] and bU[+] by using the relationship between right superior temporal gyrus and cerebellar vermis, which defines the transition from one phenotype to the other. We suggest bU[−] patients are exposed to a higher risk of developing cognitive disorders based on the alteration of secreted frizzled-related protein 1 due to progressed type 2 diabetes, which can be identified using the proposed biomarker-based classification model.
dc.description.abstract
This work was supported by the Carlos III Health Institute and the European Regional Development Fund (grant numbers: PI20/01588 and FI21/00304).
dc.format
application/pdf
dc.publisher
Oxford University Press
dc.relation
Brain Communications;7(3)
dc.relation
https://doi.org/10.1093/braincomms/fcaf213
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Diabetis no-insulinodependent
dc.subject
Cervell - Imatgeria
dc.subject
Marcadors bioquímics
dc.subject
Deteriorament cognitiu lleu
dc.subject
CHEMICALS AND DRUGS::Carbohydrates::Sugars::Monosaccharides::Hexoses::Glucose
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Diagnostic Uses of Chemicals::Radiopharmaceuticals
dc.subject
ANATOMY::Nervous System::Central Nervous System::Brain
dc.subject
Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging
dc.subject
PHENOMENA AND PROCESSES::Genetic Phenomena::Phenotype
dc.subject
DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2
dc.subject
PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurocognitive Disorders::Cognition Disorders::Cognitive Dysfunction
dc.subject
CHEMICALS AND DRUGS::Biological Factors::Biomarkers
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::hidratos de carbono::azúcares::monosacáridos::hexosas::glucosa
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos diagnósticos de sustancias químicas::radiofármacos
dc.subject
ANATOMÍA::sistema nervioso::sistema nervioso central::encéfalo
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen
dc.subject
FENÓMENOS Y PROCESOS::fenómenos genéticos::fenotipo
dc.subject
ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II
dc.subject
PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos neurocognitivos::trastornos cognitivos::disfunción cognitiva
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
dc.title
Brain [18F]FDG uptake patterns in type 2 diabetes: new phenotypes relating to biomarkers of cognitive impairment
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
